G42 Healthcare, AstraZeneca agree to manufacture innovative drugs in Abu Dhabi

By Arya M Nair, Official Reporter
  • Follow author on
G42_AstraZeneca healthcare partnership
Image Courtesy; Pixabay/Pexels

G42 Healthcare, a UAE-based AI-powered healthcare company, and AstraZeneca, a science-led biopharmaceutical company, have signed a strategic partnership agreement to locally manufacture innovative drugs in Abu Dhabi.

The binding agreement focuses on collaboration in four key areas including localizing innovative industries, research and development, innovation and sustainability at a global scale. The agreement cements the emirate’s position as a hub for research and innovation in life sciences and is the latest in a series of longstanding partnerships with key players in the pharmaceutical industry.

The agreement is in line with the National Strategy for Industry and Advanced Technology and the Make it in the Emirates initiative, which was launched by the Ministry of Industry and Advanced Technology (MoIAT) to enhance the UAE’s business environment and position as an attractive destination for local and global industrial investors.

It also supports the growth and competitiveness of national industries, innovation and adoption of advanced technologies, and the UAE’s position as a global hub for future industries.

The binding agreement was signed by Mr. Ashish Koshy, Chief Executive Officer of G42 Healthcare and Ms. Pelin Incesu, Area Vice President, Middle East and Africa at AstraZeneca.

Ashish Koshy_G42_AstraZeneca healthcare partnership
Ashish Koshy
CEO – G42 Healthcare

“We are confident in the potential of our continuing partnership with AstraZeneca which holds a robust promise for the UAE healthcare sector, primed to become a global hub for life science research and innovation. This strategic collaboration will accelerate innovation across local manufacturing, and allow us to explore greater possibilities in clinical research, to deliver life-changing treatments to patients in the UAE and across the region.”

The partnership factors into Abu Dhabi’s Industrial Strategy in doubling the size of the manufacturing sector by 2031. In its essence, the agreement will expand Abu Dhabi’s footprint in life science research and development as well as enable innovation across all streams of healthcare.

Through the supervision of similar strategic partnership agreements, DoH seeks to play a critical role in the UAE’s knowledge-based economy through the creation of unique jobs that require highly skilled workers and human capital. In line with the ‘We the UAE 2031’ plan, the agreement is expected to attract the best talents in the field of medicine, while supporting the UAE’s positioning amongst the top 10 countries in healthcare.

Mr. Sameh ElFangary, Cluster President for GCC and Pakistan at AstraZeneca, said that “AstraZeneca is honored to be a long-term, trusted partner of the UAE in bringing innovative healthcare locally, and we applaud Abu Dhabi’s ambition to become a regional life sciences hub. We are now taking our comprehensive existing partnership with G42 Healthcare to new heights, accelerating it across local manufacturing, research, innovation and sustainability. I’m confident that this partnership will contribute greatly to advancing a sustainable health ecosystem that enables transforming patient outcomes.”

Related: Mowreq & YesHealth Group to build largest indoor vertical farm in Saudi Arabia